Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Incyte Corporation

Incyte Corporation (INCY) Stock Overview

Explore Incyte Corporation’s financial performance, market position, analyst ratings, and future outlook.

INCY●NASDAQ
HealthcareBiotechnology
$129.72
$1.74(1.36%)
U.S. Market opens in 4h 22m

Incyte Corporation (INCY)

Meyka AI Score

Z

Key Financials

Market Cap26.3B
P/E Ratio16.00
EPS (TTM)$7.44
ROE0.30%
Fundamental Analysis

AI Price Forecasts

1 Month$126.31
3 Months$148.72
1 Year Target$125.00

INCY Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Incyte Corporation (NASDAQ: INCY) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, Incyte Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of INCY on the NASDAQ shows an RSI of 68.42, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $125.00 for the NASDAQ listing.

Key metrics behind Incyte Corporation's NASDAQ-traded stock include a P/E ratio of 16.00 and a market capitalization of 26.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of INCY on the NASDAQ.

Price Performance (NASDAQ: INCY)

1-Day Change
1.36%
5-Day Change
2.06%
1-Month Change
10.24%
3-Month Change
33.59%
6-Month Change
29.75%
Year-to-Date (YTD) Change
31.34%
1-Year Change
53.04%
3-Year Change
103.13%
5-Year Change
71.22%
All-Time (Max) Change
6818.40%

Contact Information

https://www.incyte.com
302 498 6700
1801 Augustine Cut-Off, Wilmington, DE, 19803

Company Facts

28,440 Employees
IPO DateNov 4, 1993
CountryUS
Actively Trading

Frequently Asked Questions